Clinical Trials
40 trialsTuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
BYLieve
Novartis
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood & Primary Tumor in ER+/HER2- MBC
Pharmassist Ltd
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Kura Oncology, Inc.
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
AstraZeneca
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
AstraZeneca
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy
Minia University
CITADEL-203
Incyte Corporation
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Case Comprehensive Cancer Center
ATRi Transition Rollover Study
Merck KGaA, Darmstadt, Germany
Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
EMD Serono
BioItaLEE
Novartis
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
Bayer
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Pfizer
Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer
Novartis
CICLADES
Institut de Cancérologie de Lorraine
A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma
Shanghai Jiatan Pharmatech Co., Ltd
EPIK-P1
Novartis
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
Celcuity Inc
ZENSHIN
AstraZeneca
POSIBA
Grupo Espanol Multidisciplinario del Cancer Digestivo
A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Novartis
VISNU-2
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase I Trial of Oral PX-866
Seagen Inc.
Study of PX-866 and Docetaxel in Solid Tumors
Seagen Inc.
Phase 1 and 2 Study of PX-866 and Cetuximab
Seagen Inc.
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
Emory University
The Oncopanel Pilot (TOP) Study
British Columbia Cancer Agency
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)
Children's Hospital Medical Center, Cincinnati
Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer
Takeda
BELLE-4
Novartis
EXIST-2
Novartis
Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma
AbbVie
Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
Children's Hospital Medical Center, Cincinnati
Yogic Breathing Changes Salivary Components
Medical University of South Carolina
Treatment of Cerebral Radiation Necrosis (CRN) With Nerve Growth Factor (NGF)
Fudan University
RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM
Children's Hospital Medical Center, Cincinnati